World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ANZCTR
Last refreshed on: 28 February 2022
Main ID:  ACTRN12614001073695
Date of registration: 07/10/2014
Prospective Registration: Yes
Primary sponsor: ASTH
Public title: A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network
Scientific title: A Multi-centre, Observational Study by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network To Determine The Clinical Characteristics, Laboratory Features, Treatments, and Clinical Outcomes in Patients with Microangiopathic Thrombocytopenia
Date of first enrolment: 01/01/2015
Target sample size: 300
Recruitment status: Recruiting
URL:  https://anzctr.org.au/ACTRN12614001073695.aspx
Study type:  Observational
Study design:  Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Retrospective;  
Phase:  Not Applicable
Countries of recruitment
Australia China Hong Kong India Japan Korea, Republic Of Malaysia New Zealand
Singapore Taiwan, Province Of China Thailand
Contacts
Name: Dr Jim Tiao   
Address:  Perth Blood Institute, Hollywood Specialist Centre 3/95 Monash Avenue Nedlands WA 6009 Australia
Telephone: +61 93601319
Email: j.tiao@wacth.org
Affiliation: 
Name: Prof Ross Baker   
Address:  Perth Blood Institute, Hollywood Specialist Centre 3/95 Monash Avenue Nedlands WA 6009 Australia
Telephone: +61 892004904
Email: ross@aptin.org
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Patients presenting to a study centre and diagnosed with microangiopathic thrombocytopenia as defined by but not limited to anaemia, thrombocytopenia (<150 x10^9/L) and evidence of fragmented red blood cells (schistocytes) on blood film.
Exclusion criteria: Patients who have non-microangiopathic thrombocytopenia and/or thrombosis where an alternate diagnosis is likely.

Patients who are unable or unwilling to provide informed consent.


Age minimum: 1 Years
Age maximum: No limit
Gender: Both males and females
Health Condition(s) or Problem(s) studied
Blood - Other blood disorders
Microangiopathic Thrombocytopenia;
Microangiopathic Thrombocytopenia
Intervention(s)
This is an observational study of previously diagnosed and treated microangiopathic thrombocytopenia (MAT) patients. MAT is a rare collection of disorders caused by the formation of intravascular aggregates of platelets resulting in microcirculatory thrombosis, red blood cell destruction and vital end-organ damage. The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatment strategies employed, and clinical outcome. Each participant will be observed for 6 months once they are enrolled in the study.
Primary Outcome(s)
To determine laboratory features microangiopathic thrombocytopenia patients. Methods for analysis include standard coagulation tests and cell counts, flow cytometry, immunoassays, activity assays and/or genotyping. [Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months]
To determine the clinical characteristics of microangiopathic thrombocytopenia including symptoms, potential precipitating factors, outcome, genetic, autoantibody and immune complex factors. Data will be collected by reviewing patients' medical records.[Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months]
To determine the treatments given for microangiopathic thrombocytopenia. Data will be collected by reviewing patients' medical records.[Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months]
Secondary Outcome(s)
To assess the value of ADAMTS13 testing in predicting disease relapse. Immunoassays and activity assays will be performed on blood samples collected at enrolment and six months post-enrolment.[Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months]
To assess the value of ADAMTS13 genetic mutations in predicting disease relapse. Genotyping will be performed on blood samples collected at enrolment and six months post-enrolment.[Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months]
To establish a MAT Biobank for further testing of novel assays used for the diagnosis and scientific understanding of MAT.[18 months]
To facilitate basic disease mechanism and translational clinical research.[3 years]
Secondary ID(s)
None
Source(s) of Monetary Support
Alexion Pharmaceuticals Australasia Pty Limited
Takeda
Australasian Society of Thrombosis and Haemostasis (ASTH)
Secondary Sponsor(s)
Asia-Pacific Society on Thrombosis and Haemostasis (APSTH)
Ethics review
Status: Approved
Approval date: 14/08/2014
Contact:
Hollywood Private Hospital Research Ethics Committee
Status: Approved
Approval date: 08/05/2015
Contact:
Health and Disability Ethics Committees
Status: Approved
Approval date: 05/02/2016
Contact:
Kementerian Keshihatan Malaysis
Status: Approved
Approval date: 25/02/2016
Contact:
NEAF: Hunter New England Human Research Ethics Committee
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history